^
Association details:
| Biomarker: | PTPN11 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) + daunorubicin (Topoisomerase II inhibitor, DNA intercalator) + mitoxantrone (Topoisomerase II inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PTPN11 mutations and Outcomes in Adult Patients with Acute Myeloid Leukemia
Published date:
11/04/2020
Excerpt:
All patients had received induction chemotherapy containing cytarabine and daunorubicin or mitoxantrone....In univariate analyses, PTPN11-mutated patients had significantly longer relapse-free survival (RFS; 5-year estimate, 55% vs 33% for PTPN11-wild type patients; P=.001...and tended to have longer overall survival (OS; 5-year estimate, 43% vs 32%; P=.06...
DOI:
https://doi.org/10.1182/blood-2020-137487